BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nep ...Middle East

SHANGHAI, Oct. 14, 2024 /PRNewswire/ -- BioCity Biopharma announced that a late-breaking clinical trial abstract of its endothelin receptor type A (ETA) selective antagonist SC0062 has been selected for oral presentation at ASN Kidney Week 2024 which will take place from October 23 to 27...

Hence then, the article about biocity will present the late breaking clinical trial data of its eta selective antagonist sc0062 at the american society of nephrology asn 2024 with simultaneous publication of the trial data in the journal of the american society of nep was published today ( Monday 14/10/2024 - 10:52 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioCity will present the late-breaking clinical trial data of its ETA selective antagonist SC0062 at the American Society of Nephrology (ASN) 2024 with simultaneous publication of the trial data in the Journal of the American Society of Nep )

Also on site :

• You're Probably Wasting $200 a Month on These Sneaky Bills
• Mindy Kaling On ‘Not Suitable For Work’ Unusual Season Order, Risqué Title & Those ‘Friends’ Comparisons
• SDG&E kickstarts process to set future rates — and City Council votes to back state bills to rein in utility costs